NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $38.93 +1.29 (+3.43%) Closing price 04:00 PM EasternExtended Trading$38.93 0.00 (0.00%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$37.86▼$39.7650-Day Range$29.03▼$41.5052-Week Range$28.54▼$54.85Volume608,726 shsAverage Volume749,821 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$69.43Consensus RatingModerate Buy Company Overview Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 87% of companies evaluated by MarketBeat, and ranked 81st out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialHarrow has a consensus price target of $69.43, representing about 78.3% upside from its current price of $38.93.Amount of Analyst CoverageHarrow has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harrow's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth644.83% Earnings GrowthEarnings for Harrow are expected to grow by 644.83% in the coming year, from $0.29 to $2.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -94.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -94.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 27.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.58% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 8.41.Change versus previous monthShort interest in Harrow has recently increased by 3.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.92 News SentimentHarrow has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Harrow this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows5 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership4.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Harrow in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $135,720.00 in company stock, which represents 0.0094% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,720.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesIs Harrow, Inc. (HROW) A Good Stock To Buy Now?June 13 at 6:10 PM | insidermonkey.comIs Harrow, Inc. (HROW) A Good Stock To Buy Now?June 13 at 5:10 PM | finance.yahoo.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 15 at 1:00 AM | InvestPub (Ad)Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?June 12 at 8:14 PM | finance.yahoo.comHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareJune 10, 2026 | globenewswire.comWhat Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?June 5, 2026 | finance.yahoo.comInsider Buying: Harrow (NASDAQ:HROW) Director Purchases 1,000 Shares of StockMay 20, 2026 | insidertrades.comInsider Buying: Harrow (NASDAQ:HROW) CFO Buys 3,500 Shares of StockMay 16, 2026 | insidertrades.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $49.00 on January 1st, 2026. Since then, HROW shares have decreased by 20.6% and is now trading at $38.93. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.31. The business earned $44.20 million during the quarter, compared to analysts' expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive trailing twelve-month return on equity of 19.59%. Read the conference call transcript. Who are Harrow's major shareholders? Harrow's top institutional shareholders include Luxor Capital Group LP (3.00%), Dimensional Fund Advisors LP (1.55%), Rice Hall James & Associates LLC (0.99%) and Blackhawk Capital Partners LLC (0.46%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary and Adrienne L Graves. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/11/2026Today6/15/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 HROW's financial health is in the Yellow zone, according to TradeSmith. HROW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year Founded2012Price Target and Rating Average Price Target for Harrow$69.43 High Price Target$88.00 Low Price Target$63.00 Potential Upside/Downside+78.3%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E Ratio134.24 P/E GrowthN/ANet Income-$5.14 million Net Margins-5.57% Pretax Margin-4.16% Return on Equity19.59% Return on Assets2.26% Debt Debt-to-Equity Ratio10.30 Current Ratio2.48 Quick Ratio2.30 Sales & Book Value Annual Sales$272.30 million Price / Sales5.33 Cash Flow$0.89 per share Price / Cash Flow43.55 Book Value$1.41 per share Price / Book27.61Miscellaneous Outstanding Shares37,280,000Free Float32,504,000Market Cap$1.45 billion OptionableOptionable Beta0.28 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:HROW) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
